Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Protagonist Therapeutics Q2 2024 GAAP EPS $(0.50) Beats $(0.69) Estimate

Author: Benzinga Newsdesk | August 06, 2024 07:52am
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.69) by 27.54 percent. This is a 26.47 percent increase over losses of $(0.68) per share from the same period last year.

Posted In: PTGX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist